Zimbabwe has turned down a substantial US health deal valued at 367 million US dollars (£272m) spanning five years because of Washington's insistence on confidential data.
This move came to light after a internal memorandum dated December was leaked, indicating that President Emmerson Mnangagwa deemed the deal was "lopsided".
An official representative has since clarified that the US was seeking biological samples for scientific study and profit while refused to share the benefits from any future medical innovations.
"We will now turn to the challenging and unfortunate task of scaling back our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had provided more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has appealed for further talks to reach a deal agreeable to all parties so the country's critical HIV treatment initiative can continue.
Broader Context
This development comes after a comparable case in Kenya, where a court suspended a related deal with the US following concerns were filed about the security of citizens' health data.
After returning to the presidency recently, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered aid for the US government, but Trump claimed its expenditure was "inefficient" and his administration was pursuing direct bilateral deals to boost transparency and accountability.
According to reports, 16 African countries have to date agreed to similar agreements, constituting over $18.3bn in committed funds.
Details of the Declined Agreement
The funds for Zimbabwe was intended to supported "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this cooperation could have provided significant benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently on antiretroviral therapy through US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana said the proposed deal was "unequal".
"Zimbabwe was being asked to share its biological resources and data over an extended period, without any corresponding assurance of benefiting from any scientific breakthroughs – like new medicines or tests – that might be developed from that shared data," Mangwana explained.
"Put simply, our country would supply the raw materials for medical research without any certainty that the end products would be accessible to our people should a future health crisis arise."
Sovereignty and International Frameworks
He also noted that the American exit from the global health body and its push of bilateral health agreements were upending frameworks previously set up through the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme designed to manage potential pandemics.
"This mechanism is intended to ensure that when a country provides its data, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the funds to create them."
The government's concerns over the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We are open to ongoing dialogue with our US partners on how future collaboration might be arranged in a way that respects the independence and interests of each country."
Medical Community Response
Medical experts stated it acknowledged the official position, but urged that negotiations should continue considering much of the nation's Aids initiatives relied on international support.
"If technical issues arise, including those relating to information security or agreement terms, these can frequently be resolved via technical clarification and mutually agreed protections," the group commented.
The halted deal underscores the continuing challenges between receiving much-needed international aid and safeguarding a country's data in an increasingly data-driven world.